Fluticasone/Vilanterol Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Fluticasone/Vilanterol Supply in 2026

If your patients have been reporting difficulty filling their Fluticasone/Vilanterol (Breo Ellipta) prescriptions, you're not alone in hearing it. While this ICS/LABA combination inhaler hasn't been placed on the FDA's formal drug shortage list, intermittent retail-level stock-outs have been a recurring issue across multiple regions.

This briefing covers the current supply picture, prescribing considerations, cost and access challenges, and tools you can share with patients to help them locate this medication.

Timeline: How We Got Here

Fluticasone Furoate/Vilanterol was FDA-approved in 2013 for COPD and subsequently approved for asthma maintenance in adults in 2017. Manufactured by GlaxoSmithKline (GSK), the Ellipta device platform has been broadly adopted due to its once-daily dosing convenience and intuitive inhaler design.

Key milestones relevant to supply:

• 2013: FDA approval for COPD (100/25 mcg strength)
• 2017: FDA approval for asthma in adults (100/25 and 200/25 mcg strengths)
• 2019: Authorized generic launched, expanding supply and reducing cost barriers
• 2020-2022: COVID-19 pandemic increased respiratory medication demand broadly; some supply chain stress observed
• 2023-2025: Supply normalized but intermittent regional stock-outs persisted, particularly during fall/winter respiratory seasons
• 2026: No formal FDA shortage; regional availability gaps continue

Prescribing Implications

For providers managing patients on Fluticasone/Vilanterol, the intermittent availability issues create several practical challenges:

Continuity of Therapy

Patients who miss doses of their maintenance ICS/LABA are at increased risk of exacerbations. When a pharmacy can't fill the prescription promptly, patients may go days without their controller medication. This is particularly concerning for patients with moderate-to-severe asthma or frequent COPD exacerbations.

Therapeutic Substitution Considerations

When Fluticasone/Vilanterol is unavailable, the most common substitutions include:

• Fluticasone Propionate/Salmeterol (Advair Diskus or HFA) — Similar ICS/LABA mechanism. Twice-daily dosing. Generics available (Wixela Inhub, AirDuo RespiClick) at significantly lower cost.
• Budesonide/Formoterol (Symbicort) — Widely available ICS/LABA. Twice-daily MDI. Approved for both asthma and COPD. Often preferred on insurance formularies.
• Mometasone/Formoterol (Dulera) — ICS/LABA MDI. Approved for asthma only; not indicated for COPD.

When substituting, consider:

• The patient's specific indication (asthma vs. COPD vs. overlap)
• Inhaler device competency — switching from DPI to MDI may require technique retraining
• Insurance formulary position of the substitute
• Whether dose equivalence is achievable

Step-Up Considerations for COPD

For COPD patients who have been on Fluticasone/Vilanterol, consider whether a step-up to triple therapy is clinically appropriate. Options include:

• Fluticasone Furoate/Umeclidinium/Vilanterol (Trelegy Ellipta) — Same Ellipta platform, once-daily dosing. Smooth transition for patients already familiar with the device.
• Budesonide/Glycopyrrolate/Formoterol (Breztri Aerosphere) — Twice-daily MDI triple therapy.

Current Availability Picture

The supply situation for Fluticasone/Vilanterol in 2026 can be characterized as:

• Manufacturing: GSK production is ongoing and stable. No reported manufacturing disruptions.
• Distribution: Wholesale supply appears adequate nationally, but last-mile distribution to retail pharmacies can be uneven.
• Retail level: Stock-outs are pharmacy-specific and often temporary (1-5 business days). More common at chain pharmacies during peak respiratory season.
• Generic availability: The authorized generic (same device, same formulation) provides an additional supply channel. Some pharmacies may stock the generic when the brand is unavailable.

Cost and Access Challenges

Cost remains a significant barrier for many patients:

• Brand cash price: $350-$450 per 30-dose inhaler
• Authorized generic cash price: $250-$350 per 30-dose inhaler
• Typical insured copay: $30-$75 depending on plan tier
• GSK savings card: Eligible commercially insured patients may pay as little as $10 (not valid for Medicare/Medicaid/Tricare)

For uninsured or underinsured patients, the GSK Patient Assistance Program provides Breo Ellipta at no cost for qualifying patients (generally household income ≤300% FPL). Applications available at GSKForYou.com.

For a patient-facing cost guide to share, see: How to Save Money on Fluticasone/Vilanterol in 2026.

Tools and Resources for Your Practice

Several tools can help your practice and your patients navigate availability challenges:

Medfinder for Providers

Medfinder for Providers helps clinicians and care teams check real-time pharmacy stock for medications like Fluticasone/Vilanterol. You can direct patients to the tool or use it within your workflow to identify pharmacies that have the medication in stock before writing the prescription.

Patient Education Resources

Share these resources with patients who are having difficulty:

• How to Find Fluticasone/Vilanterol in Stock Near You
• Alternatives to Fluticasone/Vilanterol
• Fluticasone/Vilanterol Shortage Update for Patients

Prescription Strategies

• Send prescriptions to pharmacies confirmed to have stock (check via Medfinder)
• Include "DAW 0" (Dispense as Written — substitution permitted) to allow generic dispensing
• Proactively write backup prescriptions for therapeutic alternatives
• Encourage patients to use mail-order for maintenance medications

Looking Ahead

The respiratory medication landscape continues to evolve. Key developments to watch in 2026 and beyond:

• Potential additional generic entrants for ICS/LABA combination inhalers
• Biosimilar and follow-on biologic development for severe asthma may shift some patients away from ICS/LABA therapy
• Evolving insurance formulary dynamics as payers negotiate pricing
• Continued emphasis on device-agnostic prescribing to improve fill rates

Final Thoughts

Fluticasone/Vilanterol remains an effective and well-tolerated option for asthma and COPD maintenance therapy. While there is no formal shortage, the intermittent availability issues are real and affect patient adherence. By staying informed about alternatives, leveraging tools like Medfinder for Providers, and proactively communicating with patients about refill strategies, you can help minimize disruptions to care.

For a practical workflow guide, see our companion post: How to Help Your Patients Find Fluticasone/Vilanterol in Stock.